The ministry said it received a total of 278 applications, of which 55 were selected.
This scheme required applications in three different product categories.
The first category includes special empty capsules such as biopharmacy, complex generic drugs, patented or near-expiring drugs, cell-based or gene therapy drugs, orphans, HPMC, purulan, enteric acid, etc. It contained complex excipients and plant medicines. The second category covered pharmaceutical active ingredients / major starting materials / intermediates (except those covered by previous PLI schemes).
This scheme includes reused drugs, autoimmune drugs, anti-cancer drugs, anti-diabetes drugs, anti-infective drugs, cardiovascular drugs, psychotropic drugs, anti-retroviral drugs, in vitro diagnostic devices and other India. “This is expected to provide significant impetus for investment by the pharmaceutical industry in the end to achieve the goals of the system,” the ministry said in a statement.
Beneficiaries include companies such as Sun Pharma, Aurovind Pharma, Dr. Reddies Laboratories, Lupine, Mylan, Cipla and Cipla, according to the ministry.
According to the ministry, the Cabinet’s approval is in line with Aatmanirbhar Bharat’s strategy to increase India’s manufacturing capacity by increasing investment and production and increasing exports in 10 sectors.
This scheme also aims to contribute to the diversification of products into high value products in the pharmaceutical sector. “One of the further objectives of this plan is to use state-of-the-art technology to scale and scale, thereby creating world champions from India that have the potential to penetrate the global value chain. There is. “
The PLI scheme for pharmaceutical companies to benefit 55 companies is described by the Center of HealthNews, ET HealthWorld.
Source link The PLI scheme for pharmaceutical companies to benefit 55 companies is described by the Center of HealthNews, ET HealthWorld.